CAMBRIDGE, Mass.--Millennium Pharmaceuticals here has an nounced that Wyeth-Ayerst Research has accepted three antibacterial drug targets from the company for drug candidate screening. The targets were identified in the first nine months of a collaboration between the two firms, qualifying Millennium for a milestone payment for each target plus a bonus for delivering the targets in less than a year. Wyeth is the principal pharmaceutical R&D division of American Home Products. Millennium makes heavy use of bioinformatics in its drug discovery activities.